EA200701180A1 - Способ и промежуточные продукты для получения канфосфамида и его солей, фармацевтические композиции, содержащие некоторые промежуточные продукты и их применение в качестве противораковых средств - Google Patents

Способ и промежуточные продукты для получения канфосфамида и его солей, фармацевтические композиции, содержащие некоторые промежуточные продукты и их применение в качестве противораковых средств

Info

Publication number
EA200701180A1
EA200701180A1 EA200701180A EA200701180A EA200701180A1 EA 200701180 A1 EA200701180 A1 EA 200701180A1 EA 200701180 A EA200701180 A EA 200701180A EA 200701180 A EA200701180 A EA 200701180A EA 200701180 A1 EA200701180 A1 EA 200701180A1
Authority
EA
Eurasian Patent Office
Prior art keywords
intermediate products
canphosphamide
salts
pharmaceutical compositions
compositions containing
Prior art date
Application number
EA200701180A
Other languages
English (en)
Other versions
EA016052B1 (ru
Inventor
Уилльям А. Боуланджер
Стивен Дж. Колиер
Стивен А. Истам
Деннис Л. Иди
Ронан И. Гевель
Педро Э. Эрнандес Абад
Джейсон Р. Херр
Ханс Й. Кьэрсгорд
Харолд Меклер
Роберт Э. Поломски
Стивен Р. Шоу
Павел Э. Жичкин
Original Assignee
Телик, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Телик, Инк. filed Critical Телик, Инк.
Publication of EA200701180A1 publication Critical patent/EA200701180A1/ru
Publication of EA016052B1 publication Critical patent/EA016052B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/36—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/26—Amides of acids of phosphorus containing P-halide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/44—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

В заявке описаны способ получения и промежуточные продукты для получения канфосфамида и его солей, фармацевтические композиции, содержащие некоторые промежуточные продукты, и их применение в качестве противораковых средств.
EA200701180A 2004-12-21 2005-11-23 N-α-(БЕНЗИЛОКСИКАРБОНИЛ)-L-γ-ГЛУТАМИЛ-3-[[2-[[БИС[БИС(2-ХЛОРЭТИЛ)АМИНО]ФОСФОНИЛ]ОКСИ]ЭТИЛ]СУЛЬФОНИЛ]-L-АЛАНИЛ-2(R)-ФЕНИЛГЛИЦИН ИЛИ ЕГО СОЛЬ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, ПРИМЕНЕНИЕ ЭТОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА И СПОСОБ ЛЕЧЕНИЯ РАКА С ПОМОЩЬЮ ЭТОГО СОЕДИНЕНИЯ EA016052B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/018,391 US8198247B2 (en) 2004-12-21 2004-12-21 Process for and intermediates in the preparation of canfosfamide and its salts
PCT/US2005/042693 WO2006068769A1 (en) 2004-12-21 2005-11-23 Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents

Publications (2)

Publication Number Publication Date
EA200701180A1 true EA200701180A1 (ru) 2008-04-28
EA016052B1 EA016052B1 (ru) 2012-01-30

Family

ID=36216909

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701180A EA016052B1 (ru) 2004-12-21 2005-11-23 N-α-(БЕНЗИЛОКСИКАРБОНИЛ)-L-γ-ГЛУТАМИЛ-3-[[2-[[БИС[БИС(2-ХЛОРЭТИЛ)АМИНО]ФОСФОНИЛ]ОКСИ]ЭТИЛ]СУЛЬФОНИЛ]-L-АЛАНИЛ-2(R)-ФЕНИЛГЛИЦИН ИЛИ ЕГО СОЛЬ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, ПРИМЕНЕНИЕ ЭТОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА И СПОСОБ ЛЕЧЕНИЯ РАКА С ПОМОЩЬЮ ЭТОГО СОЕДИНЕНИЯ

Country Status (15)

Country Link
US (2) US8198247B2 (ru)
EP (1) EP1827605B1 (ru)
JP (1) JP5060306B2 (ru)
KR (1) KR20070089795A (ru)
CN (1) CN101080251B (ru)
AR (1) AR052167A1 (ru)
AU (1) AU2005319579B2 (ru)
BR (1) BRPI0519141A2 (ru)
CA (1) CA2587088A1 (ru)
EA (1) EA016052B1 (ru)
IL (1) IL182835A0 (ru)
MX (1) MX2007007215A (ru)
TW (1) TW200633717A (ru)
WO (1) WO2006068769A1 (ru)
ZA (1) ZA200704318B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4521488B2 (ja) * 2008-08-21 2010-08-11 福美 森重 線維筋痛症候群の治療剤並びに筋攣縮による疼痛の治療剤
US20100056825A1 (en) * 2008-08-28 2010-03-04 Telik, Inc. Formulations of canfosfamide and their preparation
US8324426B2 (en) * 2008-08-28 2012-12-04 Telik, Inc. Formulations of canfosfamide and their preparation
CA2733732A1 (en) * 2011-02-25 2012-08-25 Telik, Inc. Formulations of canfosfamide and their preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556942A (en) * 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US6627732B1 (en) * 1998-04-16 2003-09-30 Teijin Limited Glutathione derivatives and their dosage forms
US6417397B1 (en) * 1999-10-04 2002-07-09 The Regents Of The University Of California, San Diego N-substituted alkylamino acids for use as amino-protecting groups
UA74574C2 (en) 2000-05-02 2006-01-16 Telik Inc Bis (n,n'-bis(2-halogenethyl)amino)phosphodiamates, a method for producing thereof (variants), a pharmaceutical composition containing them, and a method for the treatment of tumors
US6506739B1 (en) * 2001-05-01 2003-01-14 Telik, Inc. Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents
MX2007008255A (es) * 2005-01-06 2007-09-11 Telik Inc Tioeteres de tripeptido y tetrapeptido.

Also Published As

Publication number Publication date
EA016052B1 (ru) 2012-01-30
US8334266B2 (en) 2012-12-18
EP1827605A1 (en) 2007-09-05
CN101080251B (zh) 2012-08-29
KR20070089795A (ko) 2007-09-03
AU2005319579A1 (en) 2006-06-29
CA2587088A1 (en) 2006-06-29
US20060135409A1 (en) 2006-06-22
US8198247B2 (en) 2012-06-12
WO2006068769A1 (en) 2006-06-29
TW200633717A (en) 2006-10-01
ZA200704318B (en) 2008-09-25
AR052167A1 (es) 2007-03-07
EP1827605B1 (en) 2014-03-26
AU2005319579B2 (en) 2011-07-21
BRPI0519141A2 (pt) 2008-12-30
CN101080251A (zh) 2007-11-28
JP5060306B2 (ja) 2012-10-31
MX2007007215A (es) 2007-08-14
JP2008524327A (ja) 2008-07-10
US20120238772A1 (en) 2012-09-20
IL182835A0 (en) 2007-08-19

Similar Documents

Publication Publication Date Title
MA29136B1 (fr) Agents de potentialisation de recepteurs du glutamate
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
SE0301372D0 (sv) Novel compounds
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
EA200970156A1 (ru) Пиридизиноновые производные
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
SE0301653D0 (sv) Novel compounds
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
TW200745122A (en) New compounds I
TW200745024A (en) Carboxamide derivatives as muscarinic receptor antagonists
EA200801414A1 (ru) Кальцилитические соединения
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
SE0302546D0 (sv) New compounds
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
UY30801A1 (es) Compuestos calciliticos
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
TW200745133A (en) New compounds II
EA200701180A1 (ru) Способ и промежуточные продукты для получения канфосфамида и его солей, фармацевтические композиции, содержащие некоторые промежуточные продукты и их применение в качестве противораковых средств

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU